Technical Articles

Human epidermal growth factor receptor 2 (HER2) is a key marker for molecular typing of breast cancer. Accurate evaluation of its expression level plays a decisive role in treatment decisions. With the release of milestone studies such as DESTINY-Break04, the clinical value of HER2 low expression (IHC 1+or 2+/ISH -) breast cancer is increasingly prominent.